Plasencia

Researchers are evaluating if a combination of Venetoclax, Azacytidine, and Quizartinib works better than the standard treatment of Venetoclax and Azacytidine to treat adult patients with newly diagnosed acute myeloid leukemia AML who cannot receive standard induction therapy due to age, other health issues, or risk factors. The study aims to determine which treatment offers a better chance of overall survival. Participants will be randomly assigned to one of two treatment groups. One group will receive Azacytidine by subcutaneous injection daily for seven days in each 28-day cycle, Venetoclax orally for seven days alongside Azacytidine, and Quizartinib orally from days 8 to 21, with doses adjusted based on genetic markers. The other group will receive Azacytidine injections for seven days and Venetoclax orally for seven days per cycle without Quizartinib. Treatments continue until disease progression, unacceptable side effects, or other criteria for stopping are met. During the study, participants will have regular visits for treatment and monitoring. Researchers will collect survival information and follow up by phone or clinic visits every three months for two years after the last patient enrolls. The main outcome measured is overall survival over four years. Additional outcomes include event-free survival and complete response rates over four years. Safety and health assessments will be regularly conducted throughout the trial.

Researchers are conducting an observational study to develop and validate a specific questionnaire for women with diastasis recti abdominis DRA, a condition where the abdominal muscles separate along the midline. DRA affects many women postpartum and can lead to symptoms like lower back, pelvic, and abdominal pain, urinary incontinence, and negative impacts on body image and quality of life. The study aims to create a tool that evaluates these symptoms and their consequences beyond just anatomical measurement of muscle separation. The study involves several stages a systematic literature review to identify relevant symptoms and impacts, an online survey to gather patient-reported experiences, expert panel review to refine questionnaire items, and pilot testing with women who have DRA. After finalizing the questionnaire, researchers will validate it by assessing its reliability and accuracy in a group of adult women attending a physiotherapy clinic. Participants will also complete comparative questionnaires to measure quality of life, gastrointestinal symptoms, functioning, body image, social relationships, and psychological distress. Participants will complete the newly developed questionnaire and related surveys at the start and again after 7 to 10 days to assess consistency over time. The study involves collecting demographic data and detailed self-reported measures regarding DRA symptoms and their effects. Researchers will analyze the questionnaires psychometric properties to ensure it effectively captures the impact of DRA on womens lives. The total participation includes initial assessments and a follow-up to evaluate test-retest reliability.

Researchers are conducting an observational study to assess the safety of immunotherapy for treating Hymenoptera venom allergy, which is an allergic reaction to stings from insects like bees Apis mellifera or wasps Vespula spp.. The study also aims to evaluate how patients quality of life changes before and after receiving immunotherapy. This research will take place across multiple centers in Spain and gather data prospectively. Participants in this study are people aged 14 years and older who are allergic to Hymenoptera venom and have been recommended to receive immunotherapy with VENOX, an allergy vaccine targeting the venom of wasps or bees. The study involves monitoring patients receiving this immunotherapy as part of their clinical care, without any placebo or control group, focusing on real-world treatment safety and patient experience. During the study, participants will be followed for up to 12 months to track any adverse reactions to the immunotherapy and allergic reactions to natural insect stings. Quality of life will be assessed using questionnaires before and after treatment. Researchers will also evaluate immune response at 6 and 12 months and monitor treatment effectiveness once maintenance dosing is reached. Data collection will include safety, tolerability, and patient-reported outcomes to understand the impact of immunotherapy in real clinical settings.